Therapeutic area
First-Line Study for Advanced Colorectal Cancer with MSI and/or dMMR
Therapeutic area
Oncology — Colorectal Cancer
General profile of the patient sought
Intended for people with advanced or metastatic colorectal adenocarcinoma and confirmed MSI and/or dMMR biomarkers who have not received systemic treatment for advanced disease. Previous adjuvant chemotherapy may be permitted if progression occurred at least 12 months after the last dose. Participants must be able to swallow and absorb tablets. Eligibility also depends on previous treatments and medical history, including autoimmune conditions, immune system disorders, and diabetes, which will be reviewed by the research team.
Principal investigator
Dr. Miguel Fuentes
A clinical study comparing a targeted therapy combined with immunotherapy against immunotherapy alone as initial treatment for advanced or metastatic colorectal adenocarcinoma. It is intended for people whose tumors have microsatellite instability (MSI) and/or mismatch repair deficiency (dMMR).